Open AccessKRAS A146 Mutations Are Associated With Distinct Clinical Behavior in Patients With Colorectal Liver Metastases
Author(s) -
Iris van ‘t Erve,
Nina J. Wesdorp,
Jamie E. Medina,
Leonardo Miziara Barboza Ferreira,
Alessandro Leal,
Joost Huiskens,
Karen Bolhuis,
Jan-Hein T M van Waesberghe,
RutgerJan Swijnenburg,
Daan van den Broek,
Victor E. Velculescu,
Geert Kazemier,
Cornelis J.A. Punt,
Gerrit A. Meijer,
Remond J.A. Fijneman
Publication year - 2021
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.21.00223
Subject(s) - kras , medicine , colorectal cancer , hazard ratio , oncology , gastroenterology , mutation , cancer , biology , genetics , confidence interval , gene
Somatic KRAS mutations occur in approximately half of the patients with metastatic colorectal cancer (mCRC). Biologic tumor characteristics differ on the basis of the KRAS mutation variant. KRAS mutations are known to influence patient prognosis and are used as predictive biomarker for treatment decisions. This study examined clinical features of patients with mCRC with a somatic mutation in KRAS G12, G13, Q61, K117, or A146.